Key Strategic Partners

HTI has a strategic development relationship with Cato Research, a leading contract research and development organization (CRO) with over 300 employees worldwide. Cato Research is the core portfolio company of Cato BioVentures, a life science venture capital firm and HTI's largest shareholder. Due to its strategic affiliation with Cato BioVentures and its extensive expertise working with novel pharmaceutical products, HTI has unique strategic access to a wide range of CRO services from Cato Research to support its development of HTI-101.  Accordingly, HTI expects its HTI-101 development activities to remain financially disciplined and heavily based on flexible, real-time strategic outsourcing to Cato Research and other vendors and contract service providers in the pharmaceutical industry to avoid the significant fixed-cost financial and management burden typically associated with building and maintaining a large, fully integrated product development infrastructure. Additionally, HTIs strategic access to Cato Research's pharmaceutical industry client base provides HTI with unique access to a network of prospective pharmaceutical partners with interest in development and commercialization of HTI-101 and other cardiovascular products.